Short Interest in CARGO Therapeutics, Inc. (NASDAQ:CRGX) Declines By 5.3%

CARGO Therapeutics, Inc. (NASDAQ:CRGX - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totalling 3,400,000 shares, a decline of 5.3% from the March 31st total of 3,590,000 shares. Based on an average trading volume of 303,200 shares, the short-interest ratio is presently 11.2 days. Currently, 13.2% of the company's stock are sold short.

CARGO Therapeutics Price Performance

Shares of CARGO Therapeutics stock traded up $0.04 during trading hours on Tuesday, reaching $19.10. 100,402 shares of the company's stock were exchanged, compared to its average volume of 269,419. The business's 50 day moving average is $23.51. CARGO Therapeutics has a fifty-two week low of $13.14 and a fifty-two week high of $33.92.

CARGO Therapeutics (NASDAQ:CRGX - Get Free Report) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($1.49) earnings per share for the quarter, beating analysts' consensus estimates of ($1.62) by $0.13. As a group, sell-side analysts expect that CARGO Therapeutics will post -5.6 earnings per share for the current year.

Hedge Funds Weigh In On CARGO Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. bought a new position in shares of CARGO Therapeutics in the 4th quarter valued at about $13,333,000. RTW Investments LP bought a new position in CARGO Therapeutics during the fourth quarter worth about $119,821,000. Perceptive Advisors LLC acquired a new position in CARGO Therapeutics during the fourth quarter worth approximately $79,557,000. Finally, Wellington Management Group LLP bought a new position in shares of CARGO Therapeutics during the 4th quarter worth approximately $39,009,000. 93.16% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Jefferies Financial Group raised their price target on shares of CARGO Therapeutics from $28.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, March 22nd.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.